In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
The Health Resources and Services Administration Aug. 12 announced a modernized framework for addressing national newborn screening topics, which includes…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Health Resources and Services Administration’s Rural Maternity and Obstetrics Management Strategies Program has released a report highlighting how three…
Headline
The AHA provided comments July 21 to the Senate Committee on Health, Education, Labor and Pensions on price transparency, nursing workforce and rural…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…